Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MATRISS-II. Matrix Therapy to Reduce Ischemic Stroke Sequelae-II. A Randomized-double Blinded- Placebo Controlled Trial to Assess the Efficacy and Safety of OTR4132-MD in Patients With Acute Ischemic Stroke

NCT06700824 is registered in ClinicalTrials.gov with Organ, Tissue, Regeneration, Repair and Replacement as lead sponsor.

NCT NCT06700824
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06700824 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MATRISS-II. Matrix Therapy to Reduce Ischemic Stroke Sequelae-II. A Randomized-double Blinded- Placebo Controlled Trial to Assess the Efficacy and Safety of OTR4132-MD in Patients With Acute Ischemic Stroke
Lead sponsor
Organ, Tissue, Regeneration, Repair and Replacement
Phase
Phase 2
Overall status
Completed
Start date
March 14, 2025
Completion date
March 26, 2026
Enrollment
60 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

endovascular thrombectomy, ischemic cerebrovascular accident